News from us and our partners

Tags

Topics

0 results

News
5 January, 2018
Pixium Vision receives FDA approval to begin human clinical study of its PRIMA retinal implant in the US
News
19 December, 2017
Ecolab agrees to acquire minority ownership in finnish Metgen OY
News
11 December, 2017
Mainstay Medical Announces Positive Outcome of Interim Analysis
News
11 December, 2017
Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing
News
8 December, 2017
Highlife appoints Jose Calle Gordo as Chairman of the board
News
29 November, 2017
ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa
News
29 November, 2017
Maina Bhaman joins Sofinnova Partners as Partner
News
29 November, 2017
Maina Bhaman rejoint Sofinnova Partners en tant que Partner
News
15 November, 2017
Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.
News
15 November, 2017
Inotrem obtient le statut de médicament prioritaire (PRIME) pour sa molécule leader MOTREM™ dédiée au traitement du choc septique.
News
13 November, 2017
ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness
News
10 November, 2017
Inotrem et Roche Diagnostics signent un accord de collaboration R&D pour développer un test diagnostic dans le domaine du choc septique.
News
10 November, 2017
Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test
News
31 October, 2017
Highlife lève 12.3M€ lors d'un tour de financement mené par Sofinnova Partners
News
31 October, 2017
Highlife closes €12.3 million financing round led by Sofinnova Partners
News
20 October, 2017
Avantium nominates Kees Verhaar as supervisory board chair

Pixium Vision receives FDA approval to begin human clinical study of its PRIMA retinal implant in the US

Ecolab agrees to acquire minority ownership in finnish Metgen OY

Mainstay Medical Announces Positive Outcome of Interim Analysis

Hookipa Biotech Raises $60 million (€50 million) in an Oversubscribed Round C Financing

Highlife appoints Jose Calle Gordo as Chairman of the board

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

Maina Bhaman joins Sofinnova Partners as Partner

Maina Bhaman rejoint Sofinnova Partners en tant que Partner

Inotrem granted access to priority medicines scheme (PRIME) for its lead compound MOTREM™ in the treatment of septic shock.

Inotrem obtient le statut de médicament prioritaire (PRIME) pour sa molécule leader MOTREM™ dédiée au traitement du choc septique.

ProQR Doses First LCA 10 Patient in Clinical Trial of QR-110, ProQR’s Lead Program for Genetic Blindness

Inotrem et Roche Diagnostics signent un accord de collaboration R&D pour développer un test diagnostic dans le domaine du choc septique.

Inotrem and Roche Diagnostics sign a R&D collaboration agreement in the field of septic shock to develop a companion diagnostic test

Highlife lève 12.3M€ lors d'un tour de financement mené par Sofinnova Partners

Highlife closes €12.3 million financing round led by Sofinnova Partners

Avantium nominates Kees Verhaar as supervisory board chair